Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

PRO® and Siemens Healthineers’ Magnetom Free.Max –– Supports the Modern Treatment Pathway that allows for more ...